Exacerbations by FeNO Subgroup

Skip to main content

Exacerbations by FeNO Subgroup

EFFICACY DATA

Annualized event rate of severe exacerbations across baseline FeNO subgroups (exploratory analysis)¹

Relative risk in annualized event rate of severe exacerbations across baseline FeNO group (ppb) in QUEST¹

Adapted from the Product Monograph.

Severe exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for ≥3 days or hospitalization or emergency room visit due to asthma that required systemic corticosteroids.¹

FeNO=fractional exhaled nitric oxide; CI=confidence interval.

Relative risk in annualized event rate of severe exacerbations across baseline FeNO in QUEST (bar chart) full text

Relative risk in annualized event rate of severe exacerbations across baseline FeNO group (ppb) in QUEST¹

Adapted from the Product Monograph.

Severe exacerbations were defined as deterioration of asthma requiring the use of systemic corticosteroids for ≥3 days or hospitalization or emergency room visit due to asthma that required systemic corticosteroids.¹

FeNO=fractional exhaled nitric oxide; CI=confidence interval.

Relative risk in annualized event rate of severe exacerbations across baseline FeNO in QUEST (Forest plot) full text

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

REQUEST A VISIT

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.

DUPIXENT® (dupilumab injection) logo

Terms & Conditions

DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300228
Last updated: 06/2023

PAAB logo

Baseline characteristics

Adapted from the Product Monograph.

ACQ-5=Asthma Control Questionnaire-5; AD=atopic dermatitis; AQLQs=Asthma Quality of Life Questionnaire, Standardized Version;
AR=allergic rhinitis; EOS=blood eosinophil; FeNO=fraction of exhaled nitric oxide; FEV₁=forced expiratory volume in 1 second; ICS=inhaled corticosteroid; LABA=long-acting β2-agonist; NP=nasal polyposis; SD=standard deviation.

You are now leaving Dupixent.ca

The content of the website you are visiting is not controlled by the Dupixent.ca team. The link is being offered for your convenience and should not be viewed as an endorsement of the content, product or services offered here.

Continue to external website

Coming Soon

Bar chart showing the rate of severe exacerbations in QUEST in patients with a baseline blood EOS of greater than or equal to 300 cells per microlitre. The chart shows the data for DUPIXENT 200 mg (n=264) versus placebo (n=148) and DUPIXENT 300 mg (n=277) versus placebo (n=142) at Week 52. The y-axis is the adjusted rate of severe exacerbations per year. The x-axis label is Week 52. The adjusted rate of severe exacerbations per year for DUPIXENT 200 mg and placebo was 0.37 versus 1.08, respectively. The rate ratio was 0.34 with a 95% CI of 0.24 to 0.48. The adjusted rate of severe exacerbations per year for DUPIXENT 300 mg and placebo was 0.40 versus 1.24, respectively. The rate ratio was 0.33 with a 95% CI of 0.23 to 0.45. The data was significant with a p-value of less than 0.0001.

Bar chart showing the rate of severe exacerbations, a secondary endpoint, in DRI12544. The y-axis is the adjusted rate of severe exacerbations per year. The x-axis label is Week 24. The chart shows the data for DUPIXENT 200 mg (n=65), DUPIXENT 300 mg (n=64) and placebo (n=68). The adjusted rate of severe exacerbations per year for DUPIXENT 200 mg, 300 mg and placebo were 0.30, 0.20 and 1.04, respectively. The rate ratio for DUPIXENT 200 mg versus placebo was 0.29 with a 95% CI of 0.11 to 0.76. The rate ratio of DUPIXENT 300 mg versus placebo was 0.19 with a 95% CI of 0.07 to 0.56.

Bar chart showing the relative risk in annualized event rate of severe exacerbations across baseline FeNO group (parts per billion) in QUEST. The y-axis is the rate ratio (95% CI) versus placebo. The x-axis title is “Baseline FeNO group (parts per billion)”. The x-axis sub-titles are: “Overall”, “greater than or equal to 50”, “greater than or equal to 25 to less than 50”, and “less than 25”. The chart shows the data for DUPIXENT 300 mg versus placebo and DUPIXENT 200 mg versus placebo.

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “Overall” group is 0.54 (0.43 to 0.68) and 0.52 (0.41 to 0.66), respectively. The event rates are: 0.52 for DUPIXENT 300 mg (n=633) and 0.97 for placebo (n=321); 0.46 for DUPIXENT 200 mg (n=631) and 0.87 for placebo (n=317).

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “greater than or equal to 50” group is 0.31 (0.19 to 0.49) and 0.31 (0.18 to 0.52), respectively. The event rates are: 0.39 for DUPIXENT 300 mg (n=124) and 1.27 for placebo (n=75); 0.33 for DUPIXENT 200 mg (n=119) and 1.06 for placebo (n=71).

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “greater than or equal to 25 to less than 50” group is 0.44 (0.28 to 0.69) and 0.39 (0.24 to 0.62), respectively. The event rates are: 0.46 for DUPIXENT 300 mg (n=186) and 1.05 for placebo (n=97); 0.36 for DUPIXENT 200 mg (n=180) and 0.93 for placebo (n=91).

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “less than 25” group is 0.79 (0.57 to 1.10) and 0.75 (0.54 to 1.05), respectively. The event rates are: 0.59 for DUPIXENT 300 mg (n=317) and 0.75 for placebo (n=144); 0.52 for DUPIXENT 200 mg (n=325) and 0.69 for placebo (n=149).

Forest plot showing the relative risk in annualized event rate of severe exacerbations across FeNO group (parts per billion) in QUEST. The y-axis title is “Baseline FeNO group (parts per billion)”. The y-axis sub-titles are: “Overall”, “greater than or equal to 50”, “greater than or equal to 25 to less than 50”, and “less than 25”. The x-axis is the rate ratio versus placebo. The x-axis ranges from 0.25 to 2.0. There is a vertical dotted line at the 1.0 mark. Results to the left of this mark are favourable for DUPIXENT. Results to the right of this mark are favourable for placebo. The chart shows the data for DUPIXENT 300 mg versus placebo and DUPIXENT 200 mg versus placebo.

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “Overall” group is 0.54 (0.43 to 0.68) and 0.52 (0.41 to 0.66), respectively. The event rates are: 0.52 for DUPIXENT 300 mg (n=633) and 0.97 for placebo (n=321); 0.46 for DUPIXENT 200 mg (n=631) and 0.87 for placebo (n=317).

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “greater than or equal to 50” group is 0.31 (0.19 to 0.49) and 0.31 (0.18 to 0.52), respectively. The event rates are: 0.39 for DUPIXENT 300 mg (n=124) and 1.27 for placebo (n=75); 0.33 for DUPIXENT 200 mg (n=119) and 1.06 for placebo (n=71).

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “greater than or equal to 25 to less than 50” group is 0.44 (0.28 to 0.69) and 0.39 (0.24 to 0.62), respectively. The event rates are: 0.46 for DUPIXENT 300 mg (n=186) and 1.05 for placebo (n=97); 0.36 for DUPIXENT 200 mg (n=180) and 0.93 for placebo (n=91).

The rate ratio (95% CI) for DUPIXENT 300 mg and DUPIXENT 200 mg versus placebo in the “less than 25” group is 0.79 (0.57 to 1.10) and 0.75 (0.54 to 1.05), respectively. The event rates are: 0.59 for DUPIXENT 300 mg (n=317) and 0.75 for placebo (n=144); 0.52 for DUPIXENT 200 mg (n=325) and 0.69 for placebo (n=149).

This DUPIXENT (dupilumab injection) website is for Canadian healthcare professionals only.

Please select your province and enter your medical license number to access the website.

Province

Wrong PIN – Contact us

Submit